Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2024 | May 13, 2024 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000880242 | |
Entity Registrant Name | BIOLARGO, INC. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2024 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2024 | |
Document Transition Report | false | |
Entity File Number | 000-19709 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 65-0159115 | |
Entity Address, Address Line One | 14921 Chestnut St. | |
Entity Address, City or Town | Westminster | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 92683 | |
City Area Code | 888 | |
Local Phone Number | 400-2863 | |
Title of 12(b) Security | Common stock | |
Trading Symbol | BLGO | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 296,839,523 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
Current assets: | ||
Cash and cash equivalents | $ 4,336,000 | $ 3,539,000 |
Accounts receivable, net of allowance | 2,473,000 | 2,612,000 |
Inventories, net of allowance | 251,000 | 153,000 |
Prepaid expenses and other current assets | 116,000 | 58,000 |
Total current assets | 7,176,000 | 6,362,000 |
Equipment and leasehold improvements, net of depreciation | 1,489,000 | 662,000 |
Other non-current assets | 70,000 | 70,000 |
Investment in South Korean joint venture | 18,000 | 19,000 |
Right of use, operating lease, net of amortization | 1,068,000 | 1,092,000 |
Total assets | 9,821,000 | 8,205,000 |
Current liabilities: | ||
Total | 1,740,000 | 1,488,000 |
Debt obligation | 66,000 | 66,000 |
Contract liabilities | 261,000 | 303,000 |
Lease liability | 1,090,000 | 1,109,000 |
Deposits | 226,000 | 117,000 |
Total current liabilities | 3,404,000 | 2,710,000 |
Long-term liabilities: | ||
Long-Term Debt, Excluding Current Maturities | 284,000 | 289,000 |
Lease liability, net of current | 985,000 | 1,004,000 |
Total long-term liabilities | 1,269,000 | 1,293,000 |
Total liabilities | 4,673,000 | 4,003,000 |
STOCKHOLDERS’ EQUITY: | ||
Preferred Series A, $0.00067 Par Value, 50,000,000 Shares Authorized, no Shares Issued and Outstanding, at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.00067 Par Value, 550,000,000 Shares Authorized, 295,801,370 and 292,945,747 Shares Issued, at March 31, 2024 and December 31, 2023 | 198,000 | 196,000 |
Additional paid-in capital | 155,606,000 | 154,023,000 |
Accumulated deficit | (147,508,000) | (147,098,000) |
Accumulated other comprehensive loss | (181,000) | (277,000) |
Total BioLargo Inc. and subsidiaries stockholders’ equity | 8,115,000 | 6,844,000 |
Non-controlling interest (Note 8, 9, 10) | (2,967,000) | (2,642,000) |
Total stockholders’ equity | 5,148,000 | 4,202,000 |
Total liabilities and stockholders’ equity | 9,821,000 | 8,205,000 |
Entities, Excluding Partially Owned Subsidiary [Member] | ||
Current liabilities: | ||
Total | 1,740,000 | 1,488,000 |
Partially Owned Subsidiary [Member] | ||
Current liabilities: | ||
Total | 772,000 | 397,000 |
Lease liability | 105,000 | 105,000 |
Clyra Medical Debt Obligations [Member] | ||
Current liabilities: | ||
Long term debt | $ 234,000 | $ 234,000 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2024 | Dec. 31, 2023 |
Convertible Preferred Stock, Par Value (in dollars per share) | $ 0.00067 | $ 0.00067 |
Convertible Preferred Stock, Shares Authorized (in shares) | 50,000,000 | 50,000,000 |
Convertible Preferred Stock, Shares Issued (in shares) | 0 | 0 |
Convertible Preferred Stock, Shares Outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.00067 | $ 0.00067 |
Common stock, shares authorized (in shares) | 550,000,000 | 550,000,000 |
Common stock, shares issued (in shares) | 295,801,370 | 292,945,747 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 4,760,000 | $ 3,742,000 |
Cost of revenue | ||
Cost of Goods and Services Sold | (2,514,000) | (1,932,000) |
Gross profit | 2,246,000 | 1,810,000 |
Selling, general and administrative expenses | 2,225,000 | 1,722,000 |
Research and development | 784,000 | 565,000 |
Total operating expenses | 3,009,000 | 2,287,000 |
Operating loss | (763,000) | (477,000) |
Other (expense) income: | ||
Interest expense | (12,000) | (48,000) |
Grant income | 0 | 31,000 |
Total other expense: | (12,000) | (17,000) |
Net loss | (775,000) | (494,000) |
Net loss attributable to noncontrolling interest | (365,000) | (247,000) |
Net loss attributable to common shareholders | $ (410,000) | $ (247,000) |
Net loss per share attributable to common shareholders: | ||
Loss per share attributable to shareholders – basic and diluted (in dollars per share) | $ (0.001) | $ (0.001) |
Weighted average number of common shares outstanding: (in shares) | 294,308,798 | 280,711,278 |
Comprehensive loss: | ||
Net loss | $ (775,000) | $ (494,000) |
Foreign currency translation | 96,000 | (6,000) |
Comprehensive loss | (679,000) | (500,000) |
Comprehensive loss attributable to noncontrolling interest | (365,000) | (247,000) |
Comprehensive loss attributable to common stockholders | (314,000) | (253,000) |
Product [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | 4,575,000 | 3,548,000 |
Cost of revenue | ||
Cost of Goods and Services Sold | (2,440,000) | (1,797,000) |
Service [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | 185,000 | 194,000 |
Cost of revenue | ||
Cost of Goods and Services Sold | $ (74,000) | $ (135,000) |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) | Clyra Medical [Member] Common Stock [Member] | Clyra Medical [Member] Additional Paid-in Capital [Member] | Clyra Medical [Member] Retained Earnings [Member] | Clyra Medical [Member] AOCI Attributable to Parent [Member] | Clyra Medical [Member] Noncontrolling Interest [Member] | Clyra Medical [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] Common Stock [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] Additional Paid-in Capital [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] Retained Earnings [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] AOCI Attributable to Parent [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] Noncontrolling Interest [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Noncontrolling Interest [Member] | Total |
Balance (in shares) at Dec. 31, 2022 | 278,462,706 | |||||||||||||||||
Balance at Dec. 31, 2022 | $ 186,000 | $ 148,435,000 | $ (143,594,000) | $ (149,000) | $ (2,867,000) | $ 2,011,000 | ||||||||||||
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares) | 4,201,402 | |||||||||||||||||
Sale of stock for cash, net of offering costs of $39 (unaudited) | $ 3,000 | 797,000 | 0 | 0 | 0 | 800,000 | ||||||||||||
Stock for service (in shares) | 930,490 | |||||||||||||||||
Issuance of common stock for services (unaudited) | $ 1,000 | 206,000 | 0 | 0 | 0 | 207,000 | ||||||||||||
Stock option compensation expense (unaudited) | 0 | 195,000 | 0 | 0 | 0 | 195,000 | ||||||||||||
Clyra Medical stock options issued for services (unaudited) | 0 | 61,000 | 0 | 0 | 0 | 61,000 | ||||||||||||
Clyra Medical stock issued for services (unaudited) | $ 0 | $ 0 | $ 0 | $ 0 | $ 550,000 | $ 550,000 | 0 | 0 | 0 | 0 | 225,000 | 225,000 | ||||||
Clyra Medical Preferred Series A dividend (unaudited) | 0 | 0 | 0 | 0 | (27,000) | (27,000) | ||||||||||||
Noncontrolling interest allocation (unaudited) | 0 | 467,000 | 0 | 0 | (467,000) | 0 | ||||||||||||
Net loss | 0 | 0 | (247,000) | 0 | (247,000) | (494,000) | ||||||||||||
Foreign currency translation (unaudited) | $ 0 | 0 | 0 | (6,000) | 0 | (6,000) | ||||||||||||
Balance (in shares) at Mar. 31, 2023 | 284,122,581 | |||||||||||||||||
Balance at Mar. 31, 2023 | $ 190,000 | 150,191,000 | (143,841,000) | (155,000) | (2,833,000) | 3,552,000 | ||||||||||||
Issuance of common stock in exchange for Clyra shares (in shares) | 527,983 | |||||||||||||||||
Warrant issued for interest | $ 0 | 30,000 | 0 | 0 | 0 | 30,000 | ||||||||||||
Balance (in shares) at Dec. 31, 2023 | 292,945,747 | |||||||||||||||||
Balance at Dec. 31, 2023 | $ 196,000 | 154,023,000 | (147,098,000) | (277,000) | (2,642,000) | 4,202,000 | ||||||||||||
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares) | 2,160,348 | |||||||||||||||||
Sale of stock for cash, net of offering costs of $39 (unaudited) | $ 1,000 | 487,000 | 0 | 0 | 0 | 488,000 | ||||||||||||
Stock for service (in shares) | 288,997 | |||||||||||||||||
Issuance of common stock for services (unaudited) | $ 1,000 | 82,000 | 0 | 0 | 0 | 83,000 | ||||||||||||
Warrant exercise (unaudited) | 0 | 75,000 | 0 | 0 | 0 | 75,000 | ||||||||||||
Stock option compensation expense (unaudited) | 0 | 429,000 | 0 | 0 | 0 | 429,000 | ||||||||||||
Clyra Medical stock options issued for services (unaudited) | 0 | 59,000 | 0 | 0 | 0 | 59,000 | ||||||||||||
Clyra Medical stock issued for services (unaudited) | 0 | 52,000 | 0 | 0 | 0 | 52,000 | ||||||||||||
Clyra Medical common unit offering (unaudited) | $ 0 | $ 0 | $ 0 | $ 0 | $ 475,000 | $ 475,000 | $ 0 | $ 0 | $ 0 | $ 0 | $ 50,000 | $ 50,000 | ||||||
Clyra Medical Preferred Series A dividend (unaudited) | 0 | 0 | 0 | 0 | (86,000) | (86,000) | ||||||||||||
Noncontrolling interest allocation (unaudited) | 0 | 399,000 | 0 | 0 | (399,000) | 0 | ||||||||||||
Net loss | 0 | 0 | (410,000) | 0 | (365,000) | (775,000) | ||||||||||||
Foreign currency translation (unaudited) | $ 0 | 0 | 0 | 96,000 | 0 | 96,000 | ||||||||||||
Balance (in shares) at Mar. 31, 2024 | 295,801,370 | |||||||||||||||||
Balance at Mar. 31, 2024 | $ 198,000 | $ 155,606,000 | $ (147,508,000) | $ (181,000) | $ (2,967,000) | $ 5,148,000 | ||||||||||||
Warrant exercise (unaudited) (in shares) | 406,278 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) $ in Thousands | 3 Months Ended |
Mar. 31, 2024 USD ($) | |
Offering Cost | $ 39 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Cash flows from operating activities | ||
Net loss | $ (775,000) | $ (494,000) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
Stock option compensation expense | 488,000 | 256,000 |
Common stock issued for services | 135,000 | 207,000 |
Amortization of right-of-use operating lease assets | 24,000 | 0 |
Interest expense related to amortization of the discount on note payable | 0 | 3,000 |
Fair value of warrant issued for interest | 0 | 30,000 |
Loss on investment in South Korean joint venture | 1,000 | 6,000 |
Depreciation expense | 36,000 | 22,000 |
Changes in assets and liabilities: | ||
Accounts receivable | 139,000 | (316,000) |
Inventories | (98,000) | (17,000) |
Prepaid expenses and other assets | (58,000) | 25,000 |
Deposits | 109,000 | (71,000) |
Contract liabilities | (42,000) | 4,000 |
Lease liability, net | (19,000) | 4,000 |
Net cash provided by (used in) operating activities | 481,000 | (43,000) |
Cash flows from investing activities | ||
Equipment purchases | (863,000) | (48,000) |
Net cash used in investing activities | (863,000) | (48,000) |
Cash flows from financing activities | ||
Proceeds from sale of common stock, net of commissions | 488,000 | 800,000 |
Proceeds from warrant exercise | 75,000 | 0 |
Repayment of debt obligations | (5,000) | (50,000) |
Repayment by Clyra debt obligations | 0 | (15,000) |
Proceeds from sale of Clyra Medical preferred stock | 0 | 225,000 |
Net cash provided by financing activities | 1,083,000 | 1,510,000 |
Net effect of foreign currency translation | 96,000 | (6,000) |
Net change in cash | 797,000 | 1,413,000 |
Cash and cash equivalents at beginning of period | 3,539,000 | 1,851,000 |
Cash and cash equivalents at end of period | 4,336,000 | 3,264,000 |
Supplemental disclosures of cash flow information | ||
Interest | 12,000 | 15,000 |
Income taxes | 0 | 5,000 |
Short-term lease payments not included in lease liability | 12,000 | 13,000 |
Non-cash investing and financing activities | ||
Equipment added using capital lease | 0 | 80,000 |
Allocation of noncontrolling interest | 399,000 | 467,000 |
Preferred Series A Dividend | 86,000 | 0 |
Conversion of Clyra Common Stock to BioLargo Common Stock [Member] | ||
Non-cash investing and financing activities | ||
Conversion of Clyra common stock to BioLargo common stock | 0 | 100,000 |
BETI Common Stock [Member] | ||
Cash flows from financing activities | ||
Proceeds from sale of common stock, net of commissions | 50,000 | 550,000 |
Clyra Medical Common Stock [Member] | ||
Cash flows from financing activities | ||
Proceeds from sale of common stock, net of commissions | 475,000 | 0 |
Entities, Excluding Partially Owned Subsidiary [Member] | ||
Changes in assets and liabilities: | ||
Accounts payable and accrued expenses | 252,000 | 284,000 |
Partially Owned Subsidiary [Member] | ||
Changes in assets and liabilities: | ||
Accounts payable and accrued expenses | $ 289,000 | $ 14,000 |
Note 1 - Business and Organizat
Note 1 - Business and Organization | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1. Description of Business BioLargo, Inc. (“BioLargo”, or the “Company”) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination (per- and polyfluoroalkyl substances), advanced water and wastewater treatment, industrial odor control, air quality control, infection control, and myriad environmental remediation challenges. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may Organization We are a Delaware corporation formed in 1991. five 2006; 2009; 2022; 2014; 2016. three 2012 2023; 2017; 2019. Liquidity / Going Concern For the three March 31, 2024 March 31, 2024 While we were able to generate $481,000 net cash from operating activities during the three March 31, 2024 not third three March 31, 2024 The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to (i) continue to increase revenues, generate cash from operations, or generate cash from financing activities, (ii) convert assets such as our $2,473,000 in accounts receivable into cash; or, (iii) if necessary, reduce ongoing cash obligations by curtailing portions of our operations. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and partially owned subsidiaries BETI, BLEST and Clyra Medical. All intercompany accounts and transactions have been eliminated. The accounting and financial reporting policies of the Company conform, in all material respects, to accounting principles generally accepted in the United States of America (“GAAP”) and to general practices within the industry. The condensed consolidated financial statements in the Quarterly Report on Form 10 not 10 not December 31, 2023, 10 April 1, 2024. three March 31, 2024 not Foreign Currency The Company has designated the functional currency of BioLargo Canada, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive loss. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 BioLargo, Inc. and subsidiaries $ 4,242 $ 3,142 Clyra Medical Technologies, Inc. 94 397 Total $ 4,336 $ 3,539 Accounts Receivable In June 2016, 2016 13, January 1, 2023 Accounts receivable are customer obligations that are unconditional. Accounts receivable are presented net of an allowance for doubtful accounts for expected credit losses, which represents an estimate of amounts that may not no not March 31, 2024 December 31, 2023 Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the three March 31, 2024 2023 10% Three Months ended March 31, 2024 2023 Customer A 88 % 86 % At March 31, 2024 December 31, 2023 one March 31, 2024 December 31, 2023 Customer A 79 % 68 % Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 Raw material $ 85 $ 79 Finished goods 166 74 Total $ 251 $ 153 Other Non-Current Assets Other non-current assets consisted of (i) security deposits related to our business offices, (ii) three October 22, 2021, March 31, 2024 December 31, 2023 Patents $ 34 $ 34 Security deposits 36 36 Total $ 70 $ 70 Equity Method of Accounting On March 20, 2020, We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not three March 31, 2024 2023 Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not no three March 31, 2024 2023 Loss Per Share We report basic and diluted loss per share (“LPS”) for common and common share equivalents. Basic LPS is computed by dividing reported losses by the weighted average shares outstanding. Diluted LPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three March 31, 2024 2023 Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for doubtful accounts, asset depreciation and amortization, impairment expense, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our condensed consolidated financial statements. Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the three March 31, 2024 2023 2024 2023 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate — % 4.16 % 3.48 % 3.48 % Expected volatility — % 99 % 114 % 114 % Expected dividend yield — — — — Forfeiture rate — — — — Life in years — 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. The expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Warrants Warrants issued with our convertible and non-convertible debt instruments are accounted for under the fair value and relative fair value method. The warrant is first not. not not Non-Cash Transactions We determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: The Company’s products are sold through a contract with the customer and a written purchase order, in which the details of the contract are defined including the transaction price and method of shipment. The only performance obligation is to create and ship the product, and each product has separate pricing. Revenue is recognized at a point in time when the goods are shipped if the agreement is FOB manufacturer, and when goods are delivered if FOB destination. Revenue is recognized with a reduction for sales discounts, as appropriate and negotiated in the customer’s purchase order. Service contracts are performed through a written contract, which specifies the performance obligations and the rate at which the services will be billed, typically by time and materials. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed, or, for services related to product installations, at the completion of the installation. A few contracts have called for milestone or fixed cost payments, where we invoice an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. To date, there have been no The Company has outstanding contract liability obligations of $261,000 and $303,000 as of March 31, 2024, December 31, 2023, three March 31, 2024. March 31, 2024 December 31, 2023, March 31, 2024 December 31, 2023, not three March 31, 2024. As we generate revenues from royalties or license fees from our intellectual property, a licensee will pay a license fee in one third Government Grants We have been awarded multiple research grants from the private and public Canadian research programs. The income we receive directly from grants is recorded as other income. We have been awarded over 80 first 2015. third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no March 31, 2024 December 31, 2023 The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not March 31, 2024 December 31, 2023 100% The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized. Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments as of March 31, 2024 December 31, 2023 Leases At inception of a lease contract, we assess whether the contract is, or contains, a lease. Our assessment is based on: ( 1 2 3 not no not not 12 not March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023 Property and Equipment Property and equipment includes machinery and leasehold improvements and is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 3 - 10 years or the remaining lease term. Newly built leaseholds, additions, renewals, and betterments that significantly extend the life of the asset are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in income for the period. Noncontrolling Interest A noncontrolling interest is defined as the portion of the equity in an entity not not 810 10 20, three December 31, 2023 2022. December 31, 2023, 2022, December 31, 2023. 2023. |
Note 3 - Sale of Stock for Cash
Note 3 - Sale of Stock for Cash | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Stock Purchase Agreement [Text Block] | Note 3. Lincoln Park Financing On December 13, 2022, “2022 three may three 12 no first 2022 1 December 23, 2022. January 19, 2023. During the three March 31, 2024 2023 Unit Offerings During the three March 31, 2024 five three March 31, 2023, eleven six five 6, |
Note 4 - Debt Obligations
Note 4 - Debt Obligations | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 4. The following table summarizes our debt obligations outstanding as of March 31, 2024 December 31, 2023 not 8, March 31, 2024 December 31, 2023 Current portion of debt: SBA Paycheck Protection Program loan $ 43 $ 43 Vehicle loan, current portion 13 13 SBA EIDL Loan, matures July 2053, current portion 10 10 Total current portion of debt $ 66 $ 66 Long-term debt: SBA Paycheck Protection Program loans, matures May 2025 $ 97 $ 97 Vehicle loan, matures March 2029 51 55 SBA EIDL Loan, matures July 2053 136 137 Total long-term debt, net of current $ 284 $ 289 Total $ 350 $ 355 For the three March 31, 2024 For the three March 31, 2023 Vehicle loan On February 7, 2023, March 7, 2029. March 31, 2024, SBA Program Loans On February 7, 2022, March 31, 2024 On May 12, 2022, May 2025. In July 2020, July 2053. March 31, 2024, |
Note 5 - Share-based Compensati
Note 5 - Share-based Compensation | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | Note 5. Issuance of Common Stock in exchange for Services Payment of Officer Salaries No three March, 31, 2024. On March 31, 2023, Shares issued to Officers are unvested at the date of grant and subject to a lock-up agreement restricting vesting and sale until the earlier of (i) the consummation of a sale (in a single transaction or in a series of related transactions) of BioLargo by means of a sale of (a) a majority of the then outstanding common stock of BioLargo (whether by merger, consolidation, sale or transfer of common stock, reorganization, recapitalization or otherwise) or (b) all or substantially all of the assets of BioLargo; and (ii) the successful commercialization of BioLargo’s products or technologies as demonstrated by its receipt of at least $3,000,000 in cash, or the recognition of $3,000,000 in revenue, over a 12 Payment of Consultant and Vendor Fees On March 31, 2024 On March 31, 2023, All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4 2 not Stock Option Expense During the three March 31, 2024 2018 three March 31, 2024 2023. 2018 On June 22, 2018, 2018 “2018 may June 22, 2028. 2018 January 1 st March 31, 2024 Activity for our stock options under the 2018 three March 31, 2024 2023 Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2022 28,484,549 $ 0.19 Granted 1,320,498 0.20 Balance, March 31, 2023 29,805,047 0.19 7.5 678,000 Balance, December 31, 2023 41,108,448 $ 0.19 Granted 1,547,938 $ 0.30 Balance, March 31, 2024 42,656,386 $ 0.19 7.4 $ 5,909,000 Unvested (5,025,052 ) $ 0.20 Vested, March 31, 2024 37,631,334 $ 0.19 7.4 $ 4,455,000 ( 1 March 31, 2024 The options granted to purchase 1,547,938 shares during the three March 31, 2024 As of March 31, 2024, The options granted to purchase 1,320,498 shares during the three March 31, 2023 four 2007 On September 7, 2007, April 29, 2011, 2007 “2007 may September 7, 2017. September 2017, Activity for our stock options under the 2007 three March 31, 2024 2023 Options Outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2022 1,904,085 $ 0.56 Expired — — Balance, March 31, 2023 1,904,085 $ 0.56 1.5 $ — Balance, December 31, 2023 1,564,085 $ 0.61 Expired — — Balance, March 31, 2024 1,564,085 $ 0.61 0.9 $ — ( 1 March 31, 2024 Non-Plan Options Activity of our non-plan stock options issued for the three March 31, 2024 2023 Non-plan Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2022 19,023,829 $ 0.39 Granted 48,804 $ 0.20 Balance, March 31, 2023 19,072,633 $ 0.39 4.1 $ 88,000 Balance, December 31, 2023 17,375,044 $ 0.39 Expired (275,376 ) $ 0.44 Balance, March 31, 2024 17,099,668 $ 0.39 3.1 $ 695,000 Unvested (1,056,177 ) $ 0.26 Vested, March 31, 2024 16,043,491 $ 0.40 3.1 $ 437,000 ( 1 March 31, 2024 During the three March 31, 2024 not March 31, 2024, four During the three March 31, 2023, |
Note 6 - Warrants
Note 6 - Warrants | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Warrants [Text Block] | Note 6. We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following table: Warrants outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic value(1) Balance, December 31, 2022 49,023,398 $ 0.26 Granted 7,512,000 $ 0.25 Expired (4,684,986 ) $ 0.21 Balance, March 31, 2023 51,850,412 $ 0.26 $ 2.4 $ 122,000 Balance, December 31, 2023 51,590,300 $ 0.27 Granted 3,218,422 $ 0.25 Expired (406,278 ) $ 0.37 Exercised (600,000 ) $ 0.25 Balance, March 31, 2024 53,802,444 $ 0.26 $ 2.0 $ 4,021,000 ( 1 March 31, 2024 Warrants issued in Unit Offerings During the three March 31, 2024 six five 3 five During the three March 31, 2023, 3 six five Warrant issued in conjunction with amendment to note payable On March 6, 2023, 4, March 1, 2023”) five Warrant Fair Value We use the Black-Scholes option pricing model to determine the relative fair value of warrants issued in conjunction with debt instruments, common stock, and for services. With respect to debt instruments, relative fair value is amortized over the life of the warrant. The principal assumptions we used in applying the Black-Scholes model were as follows: 2024 2023 Risk free interest rate 4.04 – 5.28 % 3.88 – 4.27 % Expected volatility 64 87 % 40 95 % Expected dividend yield — — Forfeiture rate — — Expected life in years .5 – 5 .5 – 5 The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant. |
Note 7 - Accounts Payable and A
Note 7 - Accounts Payable and Accrued Expenses | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 7. As of March 31, 2024 Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 200 $ 1,357 $ 62 $ 44 $ 24 $ — $ (24 ) $ 1,663 Accrued payroll 13 39 22 — — 3 — 77 Total $ 1,740 As of December 31, 2023 Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 40 $ — $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — — — 251 Accrued interest 25 — — — — — — 25 Total $ 1,488 See Note 8, Amounts owed by ONM Environmental are comprised primarily of amounts owed to suppliers for goods and were not |
Note 8 - Noncontrolling Interes
Note 8 - Noncontrolling Interest - Clyra Medical | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 8. Clyra Medical As discussed in Note 2 Debt Obligations of Clyra Medical Promissory Note On April 8, 2022, April 8, 2024, may March 31, 2024 December 31, 2023 Line of Credit On June 30, 2020, may On December 13, 2022, September 30, 2024, January 9, 2023, As of March 31, 2024 December 31, 2023 Equity Transactions On December 15, 2023, one 1 During the three March 31, 2024, no As of March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023, BioLargo Conversion of Intercompany Balances In July 2023, Sales of Common Stock During the three March 31, 2024, February 28, 2027, five During the three March 31, 2023, not Sales of Series A Preferred Stock The Series A Preferred Stock offering closed in October 2023. no one may March 31, 2024 December 31, 2023, may 20% 30 may January 1, 2025, June 30, 2026. Clyra Stock Options Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2022 1,583,329 $ 0.06 Granted 42,582 1.48 Balance, March 31, 2023 1,625,911 $ 0.09 7.5 Balance, December 31, 2023 1,478,922 $ 0.06 Granted 25,833 $ 4.05 Balance, March 31, 2024 1,504,755 $ 0.38 6.8 Unvested (12,300 ) $ 2.71 Balance, March 31, 2024 1,492,455 $ 0.36 6.8 Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis. The fair value of the options issued totaled $59,000 in the three March 31, 2024 three March 31, 2023 three March 31, 2024 2023, ant of $4.50 and $2. 71 no March 31, 2024 December 31, 2023 Risk free interest rate 4.16 % 3.48 - 4.45 % Expected volatility 49 % 49 % Expected dividend yield — — Forfeiture rate — — Expected life in years 10 10 Clyra Warrants Clyra warrants outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2022 207,513 $ 3.72 Granted 72,581 $ 3.72 Balance, March 31, 2023 280,094 $ 3.72 3.5 Balance, December 31, 2023 749,911 $ 3.74 Granted 47,500 $ 7.50 Balance, March 31, 2024 797,411 $ 3.96 2.7 As part of the Clyra unit offering, it issued three Accounts Payable and Accrued Expenses At March 31, 2024 December 31, 2023 Category 2024 2023 Accounts payable $ 417 $ 135 Accrued dividend 328 $ 242 Accrued payroll 12 7 Accrued interest 15 13 Total $ 772 $ 397 |
Note 9 - BioLargo Engineering,
Note 9 - BioLargo Engineering, Science and Technologies, LLC | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Wholly-Owned Subsidiary [Text Block] | Note 9. In September 2017, three six two no five December 31, 2023 March 31, 2024, |
Note 10 - BioLargo Energy Techn
Note 10 - BioLargo Energy Technologies, Inc. | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 8. Clyra Medical As discussed in Note 2 Debt Obligations of Clyra Medical Promissory Note On April 8, 2022, April 8, 2024, may March 31, 2024 December 31, 2023 Line of Credit On June 30, 2020, may On December 13, 2022, September 30, 2024, January 9, 2023, As of March 31, 2024 December 31, 2023 Equity Transactions On December 15, 2023, one 1 During the three March 31, 2024, no As of March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023, BioLargo Conversion of Intercompany Balances In July 2023, Sales of Common Stock During the three March 31, 2024, February 28, 2027, five During the three March 31, 2023, not Sales of Series A Preferred Stock The Series A Preferred Stock offering closed in October 2023. no one may March 31, 2024 December 31, 2023, may 20% 30 may January 1, 2025, June 30, 2026. Clyra Stock Options Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2022 1,583,329 $ 0.06 Granted 42,582 1.48 Balance, March 31, 2023 1,625,911 $ 0.09 7.5 Balance, December 31, 2023 1,478,922 $ 0.06 Granted 25,833 $ 4.05 Balance, March 31, 2024 1,504,755 $ 0.38 6.8 Unvested (12,300 ) $ 2.71 Balance, March 31, 2024 1,492,455 $ 0.36 6.8 Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis. The fair value of the options issued totaled $59,000 in the three March 31, 2024 three March 31, 2023 three March 31, 2024 2023, ant of $4.50 and $2. 71 no March 31, 2024 December 31, 2023 Risk free interest rate 4.16 % 3.48 - 4.45 % Expected volatility 49 % 49 % Expected dividend yield — — Forfeiture rate — — Expected life in years 10 10 Clyra Warrants Clyra warrants outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2022 207,513 $ 3.72 Granted 72,581 $ 3.72 Balance, March 31, 2023 280,094 $ 3.72 3.5 Balance, December 31, 2023 749,911 $ 3.74 Granted 47,500 $ 7.50 Balance, March 31, 2024 797,411 $ 3.96 2.7 As part of the Clyra unit offering, it issued three Accounts Payable and Accrued Expenses At March 31, 2024 December 31, 2023 Category 2024 2023 Accounts payable $ 417 $ 135 Accrued dividend 328 $ 242 Accrued payroll 12 7 Accrued interest 15 13 Total $ 772 $ 397 |
BioLargo Energy Technologies, Inc (BETI) [Member] | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 10. BioLargo Energy Technologies, Inc. (“BETI”) was formed for the purpose of commercializing a proprietary sodium battery technology. BioLargo purchased 9,000,000 shares of its common stock upon its formation, and was its sole stockholder. During the three March 31, 2024 one three March 31, 2023, six one third As of March 31, 2024 |
Note 11 - Business Segment Info
Note 11 - Business Segment Information | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | Note 11. BioLargo has six 1. ONM Environmental -- which sells odor and volatile organic control products and services, located in Westminster, California; 2. Clyra Medical Technologies (“Clyra Medical”) -- which develops and sells medical products based on our technologies, located in Tampa, Florida; 3. BioLargo Engineering (BLEST) -- which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed, located in Oak Ridge, Tennessee; 4. BioLargo Canada, Inc. (“Canada”) – the main hub of our scientists researching and developing our technologies, operating out of the University of Alberta, Edmonton, Canada; and 5. BioLargo Energy Technologies, Inc. (“BETI”) – which is developing our proprietary battery technology. 6. BioLargo Equipment Solutions & Technologies, Inc. (“BEST”) – which manages the sales and distribution of our water treatment products and related services. Other than ONM Environmental, none third The segment information for the three March 31, 2024 2023 Three Months Ended March 31, 2024 2023 Revenue ONM Environmental $ 4,575 $ 3,543 BLEST 356 363 Clyra Medical — 6 Intersegment revenue (171 ) (170 ) Total $ 4,760 $ 3,742 Stock option expense BioLargo corporate $ (429 ) $ (195 ) Clyra Medical (59 ) (61 ) Total $ (488 ) $ (256 ) Depreciation expense BioLargo corporate $ (10 ) $ (6 ) ONM Environmental (5 ) (4 ) BLEST (19 ) (2 ) Clyra Medical (2 ) (10 ) Total $ (36 ) $ (22 ) Research and development expense BioLargo corporate $ (314 ) $ (189 ) ONM Environmental — — BLEST (352 ) (245 ) BETI (80 ) (32 ) BioLargo Canada (80 ) (135 ) Clyra Medical (121 ) (134 ) Intersegment R&D 163 170 Total $ (784 ) $ (565 ) Operating income (loss) BioLargo corporate $ (1,244 ) $ (799 ) ONM Environmental 1,798 1,387 BLEST (445 ) (368 ) BETI (155 ) (87 ) BEST (66 ) — BioLargo Canada (105 ) (184 ) Clyra Medical (546 ) (426 ) Total $ (763 ) $ (477 ) Interest expense BioLargo corporate $ (3 ) $ (36 ) ONM Environmental (2 ) (2 ) Clyra Medical (7 ) (10 ) Total $ (12 ) $ (48 ) As of March 31, 2024 BioLargo ONM BLEST CLYRA BETI BEST Canada Elimination Total Tangible assets $ 1,079 $ 5,870 $ 734 $ 949 $ 65 $ — $ 38 $ — $ 8,735 Right of use operating lease 380 — 688 — — — — — 1,068 Investment in South Korean joint venture 18 — — — — — — — 18 Total $ 1,477 $ 5,870 $ 1,422 $ 949 $ 65 $ — $ 38 $ — $ 9,821 As of December 31, 2023 BioLargo ONM BLEST CLYRA BETI BEST Canada Elimination Total Tangible assets $ 942 $ 4,624 $ 1,083 $ 432 $ 4 $ — $ 50 $ (41 ) $ 7,094 Right of use operating lease 394 — 698 — — — — — 1,092 Investment in South Korean joint venture 19 — — — — — — — 19 Total $ 1,355 $ 4,624 $ 1,781 $ 432 $ 4 $ — $ 50 $ (41 ) $ 8,205 |
Note 12 - Leases
Note 12 - Leases | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Lessor, Operating Leases [Text Block] | Note 12. Office Leases W e have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. Short-term leases less than one not three March 31, 2024 , rental expense was $88,000; three March 31, 2023 , rental expense was $83,000. The lease of our Westminster facility expires August 2024. four four December 31, 2023. one None not no March 31, 2024, seven As of December 31, 2023 , seven five BioLargo Year ending Corp / ONM BLEST Total December 31, 2024 122,000 154,000 276,000 December 31, 2025 125,000 157,000 282,000 December 31, 2026 129,000 160,000 289,000 December 31, 2027 133,000 163,000 296,000 December 31, 2028 79,000 166,000 245,000 Thereafter — 654,000 654,000 Total minimum lease payments $ 588,000 $ 1,454,000 $ 2,042,000 Less imputed interest (933,000 ) Total operating lease liability $ 1,109,000 |
Note 13 - Subsequent Events
Note 13 - Subsequent Events | 3 Months Ended |
Mar. 31, 2024 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 13. Sale of Stock for Cash From April 1, 2024, May 13, 2024, two six five 3 6 Exercise of Stock Options and Warrants From April 1, 2024, May 13, 2024, From April 1, 2024, May 13, 2024, Exchange of BETI common stock Each third April 1, 2024, |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Mar. 31, 2024 shares | |
Insider Trading Arr Line Items | |
Material Terms of Trading Arrangement [Text Block] | 5. Other Information Lincoln Park On December 13, 2022, entered $10.0 $0.00067 9B During the three March 31, 2024 766,175 $260,000 |
Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Trading Arrangement, Securities Aggregate Available Amount | 766,175 |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Cash and Cash Equivalents [Table Text Block] | March 31, 2024 December 31, 2023 BioLargo, Inc. and subsidiaries $ 4,242 $ 3,142 Clyra Medical Technologies, Inc. 94 397 Total $ 4,336 $ 3,539 |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | Three Months ended March 31, 2024 2023 Customer A 88 % 86 % March 31, 2024 December 31, 2023 Customer A 79 % 68 % |
Schedule of Inventory, Current [Table Text Block] | March 31, 2024 December 31, 2023 Raw material $ 85 $ 79 Finished goods 166 74 Total $ 251 $ 153 |
Schedule of Other Assets, Noncurrent [Table Text Block] | March 31, 2024 December 31, 2023 Patents $ 34 $ 34 Security deposits 36 36 Total $ 70 $ 70 |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2024 2023 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate — % 4.16 % 3.48 % 3.48 % Expected volatility — % 99 % 114 % 114 % Expected dividend yield — — — — Forfeiture rate — — — — Life in years — 10 10 10 |
Note 4 - Debt Obligations (Tabl
Note 4 - Debt Obligations (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | March 31, 2024 December 31, 2023 Current portion of debt: SBA Paycheck Protection Program loan $ 43 $ 43 Vehicle loan, current portion 13 13 SBA EIDL Loan, matures July 2053, current portion 10 10 Total current portion of debt $ 66 $ 66 Long-term debt: SBA Paycheck Protection Program loans, matures May 2025 $ 97 $ 97 Vehicle loan, matures March 2029 51 55 SBA EIDL Loan, matures July 2053 136 137 Total long-term debt, net of current $ 284 $ 289 Total $ 350 $ 355 |
Note 5 - Share-based Compensa_2
Note 5 - Share-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2022 28,484,549 $ 0.19 Granted 1,320,498 0.20 Balance, March 31, 2023 29,805,047 0.19 7.5 678,000 Balance, December 31, 2023 41,108,448 $ 0.19 Granted 1,547,938 $ 0.30 Balance, March 31, 2024 42,656,386 $ 0.19 7.4 $ 5,909,000 Unvested (5,025,052 ) $ 0.20 Vested, March 31, 2024 37,631,334 $ 0.19 7.4 $ 4,455,000 Options Outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2022 1,904,085 $ 0.56 Expired — — Balance, March 31, 2023 1,904,085 $ 0.56 1.5 $ — Balance, December 31, 2023 1,564,085 $ 0.61 Expired — — Balance, March 31, 2024 1,564,085 $ 0.61 0.9 $ — Non-plan Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2022 19,023,829 $ 0.39 Granted 48,804 $ 0.20 Balance, March 31, 2023 19,072,633 $ 0.39 4.1 $ 88,000 Balance, December 31, 2023 17,375,044 $ 0.39 Expired (275,376 ) $ 0.44 Balance, March 31, 2024 17,099,668 $ 0.39 3.1 $ 695,000 Unvested (1,056,177 ) $ 0.26 Vested, March 31, 2024 16,043,491 $ 0.40 3.1 $ 437,000 |
Note 6 - Warrants (Tables)
Note 6 - Warrants (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Warrants outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic value(1) Balance, December 31, 2022 49,023,398 $ 0.26 Granted 7,512,000 $ 0.25 Expired (4,684,986 ) $ 0.21 Balance, March 31, 2023 51,850,412 $ 0.26 $ 2.4 $ 122,000 Balance, December 31, 2023 51,590,300 $ 0.27 Granted 3,218,422 $ 0.25 Expired (406,278 ) $ 0.37 Exercised (600,000 ) $ 0.25 Balance, March 31, 2024 53,802,444 $ 0.26 $ 2.0 $ 4,021,000 |
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block] | 2024 2023 Risk free interest rate 4.04 – 5.28 % 3.88 – 4.27 % Expected volatility 64 87 % 40 95 % Expected dividend yield — — Forfeiture rate — — Expected life in years .5 – 5 .5 – 5 |
Note 7 - Accounts Payable and_2
Note 7 - Accounts Payable and Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 200 $ 1,357 $ 62 $ 44 $ 24 $ — $ (24 ) $ 1,663 Accrued payroll 13 39 22 — — 3 — 77 Total $ 1,740 Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 40 $ — $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — — — 251 Accrued interest 25 — — — — — — 25 Total $ 1,488 |
Note 8 - Noncontrolling Inter_2
Note 8 - Noncontrolling Interest - Clyra Medical (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Other Ownership Interests [Table Text Block] | Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2022 1,583,329 $ 0.06 Granted 42,582 1.48 Balance, March 31, 2023 1,625,911 $ 0.09 7.5 Balance, December 31, 2023 1,478,922 $ 0.06 Granted 25,833 $ 4.05 Balance, March 31, 2024 1,504,755 $ 0.38 6.8 Unvested (12,300 ) $ 2.71 Balance, March 31, 2024 1,492,455 $ 0.36 6.8 |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2024 2023 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate — % 4.16 % 3.48 % 3.48 % Expected volatility — % 99 % 114 % 114 % Expected dividend yield — — — — Forfeiture rate — — — — Life in years — 10 10 10 |
Warrants Outstanding for Noncontrolling Interest [Table Text Block] | Clyra warrants outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2022 207,513 $ 3.72 Granted 72,581 $ 3.72 Balance, March 31, 2023 280,094 $ 3.72 3.5 Balance, December 31, 2023 749,911 $ 3.74 Granted 47,500 $ 7.50 Balance, March 31, 2024 797,411 $ 3.96 2.7 |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 200 $ 1,357 $ 62 $ 44 $ 24 $ — $ (24 ) $ 1,663 Accrued payroll 13 39 22 — — 3 — 77 Total $ 1,740 Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 40 $ — $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — — — 251 Accrued interest 25 — — — — — — 25 Total $ 1,488 |
Clyra Medical [Member] | |
Notes Tables | |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | March 31, 2024 December 31, 2023 Risk free interest rate 4.16 % 3.48 - 4.45 % Expected volatility 49 % 49 % Expected dividend yield — — Forfeiture rate — — Expected life in years 10 10 |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | Category 2024 2023 Accounts payable $ 417 $ 135 Accrued dividend 328 $ 242 Accrued payroll 12 7 Accrued interest 15 13 Total $ 772 $ 397 |
Note 11 - Business Segment In_2
Note 11 - Business Segment Information (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Three Months Ended March 31, 2024 2023 Revenue ONM Environmental $ 4,575 $ 3,543 BLEST 356 363 Clyra Medical — 6 Intersegment revenue (171 ) (170 ) Total $ 4,760 $ 3,742 Stock option expense BioLargo corporate $ (429 ) $ (195 ) Clyra Medical (59 ) (61 ) Total $ (488 ) $ (256 ) Depreciation expense BioLargo corporate $ (10 ) $ (6 ) ONM Environmental (5 ) (4 ) BLEST (19 ) (2 ) Clyra Medical (2 ) (10 ) Total $ (36 ) $ (22 ) Research and development expense BioLargo corporate $ (314 ) $ (189 ) ONM Environmental — — BLEST (352 ) (245 ) BETI (80 ) (32 ) BioLargo Canada (80 ) (135 ) Clyra Medical (121 ) (134 ) Intersegment R&D 163 170 Total $ (784 ) $ (565 ) Operating income (loss) BioLargo corporate $ (1,244 ) $ (799 ) ONM Environmental 1,798 1,387 BLEST (445 ) (368 ) BETI (155 ) (87 ) BEST (66 ) — BioLargo Canada (105 ) (184 ) Clyra Medical (546 ) (426 ) Total $ (763 ) $ (477 ) Interest expense BioLargo corporate $ (3 ) $ (36 ) ONM Environmental (2 ) (2 ) Clyra Medical (7 ) (10 ) Total $ (12 ) $ (48 ) As of March 31, 2024 BioLargo ONM BLEST CLYRA BETI BEST Canada Elimination Total Tangible assets $ 1,079 $ 5,870 $ 734 $ 949 $ 65 $ — $ 38 $ — $ 8,735 Right of use operating lease 380 — 688 — — — — — 1,068 Investment in South Korean joint venture 18 — — — — — — — 18 Total $ 1,477 $ 5,870 $ 1,422 $ 949 $ 65 $ — $ 38 $ — $ 9,821 As of December 31, 2023 BioLargo ONM BLEST CLYRA BETI BEST Canada Elimination Total Tangible assets $ 942 $ 4,624 $ 1,083 $ 432 $ 4 $ — $ 50 $ (41 ) $ 7,094 Right of use operating lease 394 — 698 — — — — — 1,092 Investment in South Korean joint venture 19 — — — — — — — 19 Total $ 1,355 $ 4,624 $ 1,781 $ 432 $ 4 $ — $ 50 $ (41 ) $ 8,205 |
Note 12 - Leases (Tables)
Note 12 - Leases (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Notes Tables | |
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] | BioLargo Year ending Corp / ONM BLEST Total December 31, 2024 122,000 154,000 276,000 December 31, 2025 125,000 157,000 282,000 December 31, 2026 129,000 160,000 289,000 December 31, 2027 133,000 163,000 296,000 December 31, 2028 79,000 166,000 245,000 Thereafter — 654,000 654,000 Total minimum lease payments $ 588,000 $ 1,454,000 $ 2,042,000 Less imputed interest (933,000 ) Total operating lease liability $ 1,109,000 |
Note 1 - Business and Organiz_2
Note 1 - Business and Organization (Details Textual) | 3 Months Ended | |||
Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) | Sep. 30, 2017 | |
Number of Wholly-Owned Subsidiaries | 5 | |||
Number of Partially-Owned Subsidiaries | 3 | |||
Revenue from Contract with Customer, Including Assessed Tax | $ 4,760,000 | $ 3,742,000 | ||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | (775,000) | (494,000) | ||
Net Cash Provided by (Used in) Operating Activities | 481,000 | (43,000) | ||
Assets, Current | 7,176,000 | $ 6,362,000 | ||
Cash and Cash Equivalents, at Carrying Value | 4,336,000 | 3,539,000 | ||
Liabilities, Current | 3,404,000 | $ 2,710,000 | ||
Working Capital (Deficit) | 3,772,000 | |||
Net Cash Provided by (Used in) Operating Activities | 481,000 | (43,000) | ||
Stock Issued During Period, Value, New Issues | 488,000 | 800,000 | ||
Noncontrolling Interest, Increase from Subsidiary Equity Issuance | 52,000 | $ 225,000 | ||
Conversion of Assets, Contingency, Accounts Receivable to Cash | 2,473,000 | |||
The 2020 Unit Offering [Member] | ||||
Stock Issued During Period, Value, New Issues | 228,000 | |||
Clyra Medical Common Stock [Member] | ||||
Proceeds from Issuance or Sale of Equity | 475,000 | |||
Lincoln Park Capital Fund, LLC [Member] | ||||
Stock Issued During Period, Value, New Issues | $ 260,000 | |||
Clyra Medical Technologies [Member] | ||||
Subsidiary, Ownership Percentage, Parent | 53% | |||
BioLargo Engineering, Science & Technologies, LLC [Member] | ||||
Subsidiary, Ownership Percentage, Parent | 82% | 100% | ||
BioLargo Energy Technologies, Inc (BETI) [Member] | ||||
Subsidiary, Ownership Percentage, Parent | 96% | |||
Noncontrolling Interest, Increase from Subsidiary Equity Issuance | $ 50,000 |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) | 3 Months Ended | 12 Months Ended | |||||
Mar. 20, 2020 USD ($) | Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2022 | Oct. 22, 2021 USD ($) | |
Accounts Receivable, Allowance for Credit Loss, Current | $ 84,000 | $ 84,000 | |||||
Inventory Valuation Reserves | 212,000 | 212,000 | |||||
Number of Patents Acquired | 3 | ||||||
Income (Loss) from Equity Method Investments | (1,000) | $ (6,000) | |||||
Contract with Customer, Liability | 261,000 | 303,000 | |||||
Contract with Customer, Liability, Revenue Recognized | 42,000 | ||||||
Customer Deposit Liability, Current | 226,000 | 117,000 | |||||
Revenue Recognized from Customer Deposits | 4,000 | ||||||
Unrecognized Tax Benefits | $ 0 | 0 | |||||
Operating Lease, Weighted Average Discount Rate, Percent | 18% | ||||||
Operating Lease, Right-of-Use Asset | $ 1,068,000 | 1,092,000 | |||||
Operating Lease, Liability | $ 1,090,000 | 1,109,000 | |||||
Minimum [Member] | |||||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | ||||||
Maximum [Member] | |||||||
Property, Plant and Equipment, Useful Life (Year) | 10 years | ||||||
Canadian Government Grants [Member] | Minimum [Member] | |||||||
Grant Term (Month) | 6 months | ||||||
Canadian Government Grants [Member] | Maximum [Member] | |||||||
Grant Term (Month) | 18 months | ||||||
ONM [Member] | |||||||
Customer Deposit Liability, Current | $ 116,000 | $ 4,000 | |||||
CANADA | |||||||
Customer Deposit Liability, Current | $ 110,000 | $ 113,000 | |||||
Odin Co Ltd [Member] | |||||||
Payments to Acquire Interest in Joint Venture | $ 100,000 | ||||||
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage | 40% | 40% | |||||
Income (Loss) from Equity Method Investments | $ 1,000 | $ 6,000 | |||||
Odin Co Ltd [Member] | Tomorrow Water [Member] | |||||||
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage | 30% | ||||||
Odin Co Ltd [Member] | BKT and Tomorrow Water [Member] | |||||||
Payments to Acquire Interest in Joint Venture | $ 150,000 | ||||||
Clyra Medical Technologies [Member] | |||||||
Subsidiary, Ownership Percentage, Noncontrolling Owner | 47% | 47% | |||||
BioLargo Engineering, Science & Technologies, LLC [Member] | |||||||
Subsidiary, Ownership Percentage, Noncontrolling Owner | 23% | 18% | |||||
BioLargo Energy Technologies, Inc (BETI) [Member] | |||||||
Subsidiary, Ownership Percentage, Noncontrolling Owner | 4% | ||||||
Patents [Member] | |||||||
Intangible Assets, Net (Excluding Goodwill), Total | $ 34,000 | ||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | |||||||
Number of Major Customers | 1 | ||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member] | |||||||
Concentration Risk, Percentage | 10% |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
Cash and Cash Equivalents, at Carrying Value | $ 4,336,000 | $ 3,539,000 |
Parent Company [Member] | ||
Cash and Cash Equivalents, at Carrying Value | 4,242,000 | 3,142,000 |
Noncontrolling Interest [Member] | ||
Cash and Cash Equivalents, at Carrying Value | $ 94,000 | $ 397,000 |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details) - Customer A [Member] - Customer Concentration Risk [Member] | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Accounts Receivable [Member] | |||
Credit concentration | 79% | 68% | |
Revenue from Contract with Customer Benchmark [Member] | |||
Credit concentration | 88% | 86% |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Raw material | $ 85 | $ 79 |
Finished goods | 166 | 74 |
Total | $ 251 | $ 153 |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies - Other Non-current Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Patents | $ 34 | $ 34 |
Security deposits | 36 | 36 |
Total | $ 70 | $ 70 |
Note 2 - Summary of Significa_8
Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details) | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Non Plan [Member] | ||
Expected volatility | 99% | |
Expected dividend yield | 0% | |
Forfeiture rate | 0% | |
Expected life in years (Year) | 10 years | |
Non Plan [Member] | Minimum [Member] | ||
Risk free interest rate | 0% | |
Non Plan [Member] | Maximum [Member] | ||
Risk free interest rate | 3.48% | |
Expected volatility | 114% | |
Expected life in years (Year) | 10 years | |
2018 Equity Incentive Plan [Member] | Minimum [Member] | ||
Risk free interest rate | 3.48% | |
Expected volatility | 114% | |
Expected life in years (Year) | 10 years |
Note 3 - Sale of Stock for Ca_2
Note 3 - Sale of Stock for Cash (Details Textual) | 3 Months Ended | ||
Mar. 31, 2024 USD ($) shares | Mar. 31, 2023 USD ($) shares | Dec. 13, 2022 USD ($) | |
Proceeds from Issuance of Common Stock | $ 488,000 | $ 800,000 | |
Warrants Issued with 2020 Unit Offering [Member] | Minimum [Member] | |||
Warrants and Rights Outstanding, Term (Year) | 6 years | ||
Warrants Issued with 2020 Unit Offering [Member] | Maximum [Member] | |||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||
The 2020 Unit Offering [Member] | |||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 1,394,173 | 3,656,000 | |
Proceeds From Issuance of Common Stock, Gross | $ 267,000 | $ 695,000 | |
Proceeds from Issuance of Common Stock | $ 228,000 | ||
Number of Accredited Investors | 5 | 11 | |
Lincoln Park Capital Fund, LLC [Member] | |||
Stock Purchase Agreement, Maximum Amount of Common Stock | $ 10,000,000 | ||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 766,175 | 545,402 | |
Proceeds From Issuance of Common Stock, Gross | $ 260,000 | $ 105,000 |
Note 4 - Debt Obligations (Deta
Note 4 - Debt Obligations (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | |||||
Feb. 07, 2023 | Feb. 07, 2022 | Jul. 31, 2020 | Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | May 12, 2022 | |
Interest Expense, Debt | $ 12,000 | $ 48,000 | |||||
Paycheck Protection Program CARES Act [Member] | ONM [Member] | |||||||
Extinguishment of Debt, Amount | $ 174,000 | ||||||
Proceeds from Issuance of Debt | $ 217,000 | ||||||
Long-Term Debt | $ 43,000 | ||||||
Paycheck Protection Program CARES Act [Member] | BioLargo Engineering, Science & Technologies, LLC [Member] | |||||||
Long-Term Debt | $ 97,000 | ||||||
Economic Injury Disaster Loan [Member] | ONM [Member] | |||||||
Debt Instrument, Face Amount | $ 150,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 3.75% | ||||||
Debt Instrument, Periodic Payment | $ 700 | ||||||
Debt Instrument, Outstanding Balance | 146,000 | ||||||
Vehicle Loan [Member] | |||||||
Debt Instrument, Face Amount | $ 80,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.29% | ||||||
Debt Instrument, Periodic Payment | $ 1,000 | ||||||
Debt Instrument, Outstanding Balance | $ 64,000 |
Note 4 - Debt Obligations - Sch
Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Total current portion of debt | $ 66 | $ 66 |
Total long-term debt, net of current | 284 | 289 |
Total | 350 | 355 |
Vehicle Loan [Member] | ||
Long-term debt, current | 13 | 13 |
Total long-term debt, net of current | 51 | 55 |
Paycheck Protection Program CARES Act [Member] | ||
SBA Paycheck Protection Program loan | 43 | 43 |
SBA Paycheck Protection Program loans, matures May 2025 | 97 | 97 |
Economic Injury Disaster Loan [Member] | ||
Long-term debt, current | 10 | 10 |
Total long-term debt, net of current | $ 136 | $ 137 |
Note 5 - Share-based Compensa_3
Note 5 - Share-based Compensation (Details Textual) - USD ($) | 3 Months Ended | ||||
Mar. 31, 2023 | Jun. 22, 2018 | Sep. 07, 2017 | Mar. 31, 2024 | Mar. 31, 2023 | |
Stock Issued During Period, Value, Issued for Services | $ 83,000 | $ 207,000 | |||
Share Price (in dollars per share) | $ 0.35 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | ||||
Remaining Stock Option Plan Expense | $ 1,056,000 | ||||
Stock Option Plan Expense, Period of Recognition (Year) | 4 years | ||||
2018 Equity Incentive Plan [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year (in shares) | 2,000,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 52,000,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 9,343,614 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 1,547,938 | 1,320,498 | |||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 5,025,000 | ||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 4 years | ||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.3 | $ 0.2 | |||
Equity Incentive Plan 2007 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||
Non Plan [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 48,804 | ||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.2 | ||||
Share-Based Payment Arrangement, Option [Member] | Clyra Medical Technologies [Member] | |||||
Share-Based Payment Arrangement, Expense | $ 59,000 | $ 61,000 | |||
Selling, General and Administrative Expenses [Member] | |||||
Share-Based Payment Arrangement, Expense | $ 488,000 | $ 256,000 | |||
Officer [Member] | |||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 30,747 | 0 | |||
Stock Issued During Period, Value, Issued for Services | $ 6,000 | ||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.2 | $ 0.2 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Cash Amount Receipt | $ 3,000,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Revenue Required | $ 3,000,000 | ||||
Consultants [Member] | |||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 250,639 | 899,743 | |||
Stock Issued During Period, Value, Issued for Services | $ 83,000 | $ 201,000 | |||
Shares Issued, Price Per Share (in dollars per share) | $ 0.2 | $ 0.35 | $ 0.2 | ||
Board of Directors, Employees, and Consultants [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 1,547,938 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 418,000 | ||||
Board of Directors, Employees, and Consultants [Member] | 2018 Equity Incentive Plan [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 544,841 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 173,000 | ||||
Board Of Directors [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 267,746 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 85,000 | ||||
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 347,730 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 65,000 | ||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.2 | ||||
Employees [Member] | Employee Retention Program [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 735,351 | 570,204 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 160,000 | $ 108,000 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 4 years | ||||
Employees [Member] | Employee Retention Program [Member] | Maximum [Member] | |||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.2 | ||||
Officer, Board of Directors, Employees, and a Consultant [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 1,320,498 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 248,000 | ||||
Employees and Consultants [Member] | 2018 Equity Incentive Plan [Member] | |||||
Stock Issued During Period, Value, Issued for Services | $ 19,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 102,564 | ||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.2 | ||||
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 300,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 56,000 | ||||
Vendors [Member] | Non Plan [Member] | |||||
Share-Based Payment Arrangement, Expense | $ 9,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 48,804 | ||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.2 |
Note 5 - Share-based Compensa_4
Note 5 - Share-based Compensation - Stock Options (Details) - USD ($) | 3 Months Ended | |||
Mar. 31, 2024 | Mar. 31, 2023 | |||
Options outstanding, Granted (in shares) | 0 | |||
2018 Equity Incentive Plan [Member] | ||||
Options outstanding, balance (in shares) | 41,108,448 | 28,484,549 | ||
Weighted average exercise price, balance (in dollars per share) | $ 0.19 | $ 0.19 | ||
Options outstanding, Granted (in shares) | 1,547,938 | 1,320,498 | ||
Weighted average exercise price, Granted (in dollars per share) | $ 0.3 | $ 0.2 | ||
Weighted average remaining term, Outstanding (Year) | 7 years 4 months 24 days | 7 years 6 months | ||
Aggregate intrinsic Value, Balance | $ 5,909,000 | $ 678,000 | [1] | |
Options outstanding, balance (in shares) | 42,656,386 | 29,805,047 | ||
Weighted average exercise price, balance (in dollars per share) | $ 0.19 | $ 0.19 | ||
Unvested (in shares) | (5,025,052) | |||
Weighted average exercise price per share, unvested (in dollars per share) | $ 0.2 | |||
Options outstanding, Vested (in shares) | 37,631,334 | |||
Weighted average exercise price, Vested (in dollars per share) | $ 0.19 | |||
Weighted average remaining term, Vested (Year) | 7 years 4 months 24 days | |||
Aggregate intrinsic value, Vested | [1] | $ 4,455,000 | ||
The 2007 Equity Incentive Plan [Member] | ||||
Options outstanding, balance (in shares) | 1,564,085 | 1,904,085 | ||
Weighted average remaining term, Outstanding (Year) | 10 months 24 days | 1 year 6 months | ||
Options outstanding, balance (in shares) | 1,564,085 | 1,904,085 | ||
Options outstanding, Expired (in shares) | 0 | 0 | ||
The 2007 Equity Incentive Plan [Member] | Minimum [Member] | ||||
Weighted average exercise price, balance (in dollars per share) | $ 0.61 | $ 0.56 | ||
Weighted average exercise price, balance (in dollars per share) | 0.61 | 0.56 | ||
Weighted average exercise price per share, Expired (in dollars per share) | $ 0 | $ 0 | ||
Non Plan [Member] | ||||
Options outstanding, balance (in shares) | 17,375,044 | 19,023,829 | ||
Weighted average exercise price, balance (in dollars per share) | $ 0.39 | $ 0.39 | ||
Options outstanding, Granted (in shares) | 48,804 | |||
Weighted average exercise price, Granted (in dollars per share) | $ 0.2 | |||
Weighted average remaining term, Outstanding (Year) | 3 years 1 month 6 days | 4 years 1 month 6 days | ||
Options outstanding, balance (in shares) | 17,099,668 | 19,072,633 | ||
Weighted average exercise price, balance (in dollars per share) | $ 0.39 | $ 0.39 | ||
Unvested (in shares) | (1,056,177) | |||
Weighted average exercise price per share, unvested (in dollars per share) | $ 0.26 | |||
Options outstanding, Vested (in shares) | 16,043,491 | |||
Weighted average exercise price, Vested (in dollars per share) | $ 0.4 | |||
Weighted average remaining term, Vested (Year) | 3 years 1 month 6 days | |||
Aggregate intrinsic value, Vested | $ 437,000 | |||
Options outstanding, Expired (in shares) | (275,376) | |||
Weighted average exercise price per share, Expired (in dollars per share) | $ 0.44 | |||
Aggregate intrinsic value, balance | $ 695,000 | $ 88,000 | [1] | |
[1]Aggregate intrinsic value based on closing common stock price of $0.35 at March 31, 2024. |
Note 6 - Warrants (Details Text
Note 6 - Warrants (Details Textual) - USD ($) | Mar. 31, 2024 | Mar. 31, 2023 | Mar. 06, 2023 | |
Share Price (in dollars per share) | $ 0.35 | |||
Warrants and Rights Outstanding | $ 4,021,000 | $ 122,000 | [1] | |
Note Payable, Maturing March 8, 2023 [Member] | ||||
Debt Instrument, Face Amount | $ 50,000 | |||
Six-month Warrants in Connection With the 2020 Unit Offering [Member] | ||||
Warrants and Rights Outstanding, Term (Year) | 6 months | 6 months | ||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1,394,737 | 3,656,000 | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.23 | $ 0.23 | ||
Five-year Warrants in Connection With the 2020 Unit Offering [Member] | ||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1,394,737 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.29 | |||
Five Year Warrants in Connection with the 2020 Unit Offering, Commissions [Member] | ||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.19 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 428,948 | |||
Warrants and Rights Outstanding, Fair Value | $ 201,000 | |||
Five-month Warrants in Connection With the 2020 Unit Offering [Member] | ||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 3,656,000 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.29 | |||
Warrants and Rights Outstanding, Fair Value | $ 1,097,000 | |||
Warrants Issued in Connection with Conversion of Interest on Note Payable Maturing March 8, 2023 [Member] | ||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 200,000 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.21 | |||
Warrants and Rights Outstanding | $ 30,000 | |||
[1]Aggregate intrinsic value based on closing common stock price of $0.35 at March 31, 2024. |
Note 6 - Warrants - Warrants Ou
Note 6 - Warrants - Warrants Outstanding (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | ||
Warrants outstanding, balance (in shares) | 51,590,300 | 49,023,398 | |
Warrants outstanding, Granted (in shares) | 3,218,422 | 7,512,000 | |
Warrants outstanding, Expired (in shares) | (406,278) | (4,684,986) | |
Weighted average remaining life, balance (Year) | 2 years | 2 years 4 months 24 days | |
Balance, aggregate intrinsic value | $ 4,021,000 | $ 122,000 | [1] |
Warrants outstanding, Exercised (in shares) | (600,000) | ||
Warrants outstanding, balance (in shares) | 53,802,444 | 51,850,412 | |
Weighted Average [Member] | |||
Weighted average price, balance (in dollars per share) | $ 0.27 | $ 0.26 | |
Weighted average price, Granted (in dollars per share) | 0.25 | 0.25 | |
Weighted average price, Expired (in dollars per share) | 0.37 | 0.21 | |
Weighted average price, Exercised (in dollars per share) | 0.25 | ||
Weighted average price, balance (in dollars per share) | $ 0.26 | $ 0.26 | |
[1]Aggregate intrinsic value based on closing common stock price of $0.35 at March 31, 2024. |
Note 6 - Warrants - Assumptions
Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details) - Measurement Input, Risk Free Interest Rate [Member] | Mar. 31, 2024 | Dec. 31, 2023 |
Minimum [Member] | ||
Risk free interest rate | 0.0404 | 0.0388 |
Maximum [Member] | ||
Risk free interest rate | 0.0528 | 0.0427 |
Note 7 - Accounts Payable and_3
Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Accounts payable | $ 1,663 | $ 1,212 |
Accrued payroll | 77 | 251 |
Total | 1,740 | 1,488 |
Accrued interest | 25 | |
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | ||
Accounts payable | 200 | 163 |
Accrued payroll | 13 | 49 |
Accrued interest | 25 | |
Operating Segments [Member] | Odor-No-More [Member] | ||
Accounts payable | 1,357 | 964 |
Accrued payroll | 39 | 86 |
Accrued interest | 0 | |
Operating Segments [Member] | BLEST [Member] | ||
Accounts payable | 62 | 34 |
Accrued payroll | 22 | 116 |
Accrued interest | 0 | |
Operating Segments [Member] | BioLargo Canada [Member] | ||
Accounts payable | 44 | 93 |
Accrued payroll | 0 | 0 |
Accrued interest | 0 | |
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] | ||
Accounts payable | 24 | 40 |
Accrued payroll | 0 | 0 |
Accrued interest | 0 | |
Operating Segments [Member] | BEST [Member] | ||
Accounts payable | 0 | 0 |
Accrued payroll | 3 | 0 |
Accrued interest | 0 | |
Consolidation, Eliminations [Member] | ||
Accounts payable | (24) | (82) |
Accrued payroll | $ 0 | 0 |
Accrued interest | $ 0 |
Note 8 - Noncontrolling Inter_3
Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual) | 1 Months Ended | 3 Months Ended | |||||||
Dec. 15, 2023 | Jun. 30, 2020 USD ($) shares | Jul. 31, 2023 USD ($) shares | Jan. 31, 2023 shares | Mar. 31, 2024 USD ($) $ / shares shares | Mar. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2023 USD ($) shares | Apr. 08, 2022 USD ($) | ||
Long-Term Line of Credit | $ 134,000 | $ 134,000 | |||||||
Research and Development Expense | $ 784,000 | $ 565,000 | |||||||
Preferred Stock, Shares Outstanding (in shares) | shares | 0 | 0 | |||||||
Common Stock, Shares, Issued (in shares) | shares | 295,801,370 | 292,945,747 | |||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 0 | 225,000 | |||||||
Warrants and Rights Outstanding | $ 4,021,000 | $ 122,000 | [1] | ||||||
Share Price (in dollars per share) | $ / shares | $ 0.35 | ||||||||
Clyra Medical [Member] | Common Stock [Member] | |||||||||
Investment Owned, Balance, Shares (in shares) | shares | 5,322,775 | 5,322,775 | |||||||
Clyra Medical [Member] | Preferred Stock, Series A [Member] | |||||||||
Investment Owned, Balance, Shares (in shares) | shares | 165,765 | 165,765 | |||||||
Clyra Medical [Member] | |||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 100 | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 27,600 | 0 | |||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 2.71 | ||||||||
Research and Development Expense | $ 52,000 | ||||||||
Stock Issued, Discount on Fair Value, Percentage | 30% | ||||||||
Shares, Outstanding (in shares) | shares | 10,095,749 | ||||||||
Common Stock, Shares, Outstanding (in shares) | shares | 10,000,749 | ||||||||
Common Stock, Shares, Issued (in shares) | shares | 95,000 | ||||||||
Preferred Stock Dividends and Other Adjustments | $ 327,000 | $ 241,000 | |||||||
Clyra Medical [Member] | Share-Based Payment Arrangement, Option [Member] | Employees and Consultants [Member] | |||||||||
Share-Based Payment Arrangement, Expense | $ 59,000 | $ 61,000 | |||||||
Share Price (in dollars per share) | $ / shares | $ 4.5 | $ 2.71 | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate | 30% | ||||||||
Clyra Medical [Member] | Warrants Expiring February 28, 2027 [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 47,500 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 7.5 | ||||||||
Number of Accredited Investors | 5 | ||||||||
Proceeds from Issuance or Sale of Equity | $ 475,000 | ||||||||
Clyra Medical [Member] | Warrants Issued in Conjunction With the Sale of Series A Preferred Stock [Member] | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 3.72 | ||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||||
Warrants and Rights Outstanding | $ 524,000 | ||||||||
Clyra Medical [Member] | Clyra Unit Offering [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 47,500 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 7.5 | ||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||||
Warrants and Rights Outstanding | $ 57,000 | ||||||||
Clyra Medical [Member] | Preferred Shares Issued for Debt Owed to Biolargo [Member] | |||||||||
Debt Conversion, Converted Instrument, Amount | $ 96,000 | ||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 30,833 | ||||||||
Clyra Medical [Member] | Preferred Class A [Member] | |||||||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 746,618 | ||||||||
Preferred Stock, Shares Outstanding (in shares) | shares | 746,418 | ||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 1,800,000 | ||||||||
Clyra Medical [Member] | Series A Preferred Stock [Member] | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 3.1 | ||||||||
Preferred Stock, Shares Outstanding (in shares) | shares | 746,418 | ||||||||
Preferred Stock, Dividend Rate, Percentage | 15% | ||||||||
Preferred Stock, Convertible, Sale of Stock Amount | $ 5,000,000 | ||||||||
Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member] | |||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 1,000,000 | ||||||||
Proceeds from Lines of Credit, Total | $ 260,000 | ||||||||
Repayments of Lines of Credit | 126,000 | ||||||||
Stock Issued During Period, Shares, Commitment Fee (in shares) | shares | 32,200 | ||||||||
Stock Issued During Period, Value, Commitment Fee | $ 70,000 | ||||||||
Debt Instrument, Percentage of Principal Payment, Cap | 15% | ||||||||
Clyra Medical [Member] | Notes Payable, Other Payables [Member] | |||||||||
Debt Instrument, Face Amount | $ 100,000 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | ||||||||
Debt Instrument, Convertible, Sale of Stock Amount | $ 5,000,000 | ||||||||
Debt Instrument, Convertible, Conversion Percentage | 70% | ||||||||
Debt Instrument, Outstanding Balance | $ 100,000 | $ 100,000 | |||||||
Vernal Bay Capital Group, LLC [Member] | Conversion of Clyra Medical Stock Into Biolargo Common Stock [Member] | |||||||||
Stock Issued During Period, Shares, Commitment Fee (in shares) | shares | 32,200 | ||||||||
Conversion of Stock, Shares Issued (in shares) | shares | 527,983 | ||||||||
[1]Aggregate intrinsic value based on closing common stock price of $0.35 at March 31, 2024. |
Note 8 - Noncontrolling Inter_4
Note 8 - Noncontrolling Interest - Clyra Medical - Common Shares Outstanding (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Options outstanding, Granted (in shares) | 0 | |
Clyra Medical [Member] | ||
Clyra options outstanding, balance (in shares) | 1,478,922 | 1,583,329 |
Weighted average price, balance (in dollars per share) | $ 0.06 | $ 0.06 |
Options outstanding, Granted (in shares) | 25,833 | 42,582 |
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 4.05 | $ 1.48 |
Weighted average remaining term, Outstanding (Year) | 6 years 9 months 18 days | 7 years 6 months |
Clyra options outstanding, balance (in shares) | 1,504,755 | |
Weighted average price, balance (in dollars per share) | $ 0.38 | |
Balance, Weighted Average Remaining Term (Year) | 6 years 9 months 18 days | 7 years 6 months |
Unvested (in shares) | (12,300) | |
Weighted average price, Unvested (in dollars per share) | $ 2.71 | |
Clyra options outstanding, balance (in shares) | 1,492,455 | 1,625,911 |
Weighted average price, balance (in dollars per share) | $ 0.36 | $ 0.09 |
Note 8 - Noncontrolling Inter_5
Note 8 - Noncontrolling Interest - Clyra Medical - Valuation Assumptions (Details) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Clyra Medical [Member] | Vendors and Employees [Member] | |||
Risk free interest rate | 3.48% | 4.45% | |
Minimum [Member] | Clyra Medical [Member] | Vendors and Employees [Member] | |||
Expected life in years (Year) | 10 years | ||
Maximum [Member] | Clyra Medical [Member] | Vendors and Employees [Member] | |||
Expected volatility | 49% | ||
Expected life in years (Year) | 10 years | ||
Non Plan [Member] | |||
Expected volatility | 99% | ||
Expected life in years (Year) | 10 years | ||
Non Plan [Member] | Minimum [Member] | |||
Risk free interest rate | 0% | ||
Non Plan [Member] | Minimum [Member] | Clyra Medical [Member] | Vendors and Employees [Member] | |||
Risk free interest rate | 4.16% | ||
Expected volatility | 49% | ||
Non Plan [Member] | Maximum [Member] | |||
Risk free interest rate | 3.48% | ||
Expected volatility | 114% | ||
Expected life in years (Year) | 10 years |
Note 8 - Noncontrolling Inter_6
Note 8 - Noncontrolling Interest - Clyra Medical - Warrants Outstanding (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Warrants outstanding, balance (in shares) | 51,590,300 | 49,023,398 |
Weighted average remaining life, balance (Year) | 2 years | 2 years 4 months 24 days |
Warrants outstanding, balance (in shares) | 53,802,444 | 51,850,412 |
Clyra Medical [Member] | ||
Warrants outstanding, balance (in shares) | 749,911 | 207,513 |
Granted Warrants, Balance (in shares) | 47,500 | 72,581 |
Weighted average remaining life, balance (Year) | 2 years 8 months 12 days | 3 years 6 months |
Warrants outstanding, balance (in shares) | 797,411 | 280,094 |
Clyra Medical [Member] | Minimum [Member] | ||
Outstanding Warrants, Weighted Average Price Per Share (in dollars per share) | $ 3.74 | $ 3.72 |
Granted Warrants, Weighted Average Price Per Share (in dollars per share) | 7.5 | 3.72 |
Outstanding Warrants, Weighted Average Price Per Share (in dollars per share) | $ 3.96 | $ 3.72 |
Note 8 - Noncontrolling Inter_7
Note 8 - Noncontrolling Interest - Clyra Medical - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Accounts payable | $ 1,663 | $ 1,212 |
Accrued payroll | 77 | 251 |
Accrued interest | 25 | |
Accounts payable and accrued expenses, total | 1,740 | 1,488 |
Clyra Medical [Member] | ||
Accounts payable | 417 | 135 |
Accrued dividend | 328 | 242 |
Accrued payroll | 12 | 7 |
Accrued interest | 15 | 13 |
Accounts payable and accrued expenses, total | $ 772 | $ 397 |
Note 9 - BioLargo Engineering_2
Note 9 - BioLargo Engineering, Science and Technologies, LLC (Details Textual) - shares | 1 Months Ended | 3 Months Ended | |
Sep. 30, 2017 | Mar. 31, 2024 | Dec. 31, 2023 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | ||
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | |||
Percentage of Profits Interests Vested | 22.50% | 22.50% | |
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Non-Qualified Stock Option [Member] | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 1,750,000 | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 5 years | ||
BioLargo Engineering, Science & Technologies, LLC [Member] | |||
Subsidiary, Ownership Percentage, Parent | 100% | 82% |
Note 10 - BioLargo Energy Tec_2
Note 10 - BioLargo Energy Technologies, Inc. (Details Textual) | 3 Months Ended | |
Mar. 31, 2024 USD ($) $ / shares shares | Mar. 31, 2023 $ / shares shares | |
Share Price (in dollars per share) | $ / shares | $ 0.35 | |
BioLargo Energy Technologies, Inc (BETI) [Member] | ||
Investment Owned, Balance, Shares (in shares) | 9,050,000 | |
Third Party [Member] | Conversion Debt to Equity [Member] | ||
Proceeds from Issuance or Sale of Equity | $ | $ 550,000 | |
BioLargo Energy Technologies, Inc (BETI) [Member] | ||
Investment Owned, Balance, Shares (in shares) | 9,000,000 | |
Stock Issued During Period, Shares, New Issues (in shares) | 20,000 | 325,000 |
Share Price (in dollars per share) | $ / shares | $ 2.5 | $ 2 |
Number of Accredited Investors | 1 | 6 |
Proceeds from Issuance or Sale of Equity | $ | $ 50,000 | |
Shares, Outstanding (in shares) | 9,467,000 | |
BioLargo Energy Technologies, Inc (BETI) [Member] | Conversion Debt to Equity [Member] | ||
Conversion of Stock, Shares Issued (in shares) | 25,000 | |
BioLargo Energy Technologies, Inc (BETI) [Member] | Biolargo [Member] | ||
Proceeds from Issuance or Sale of Equity | $ | $ 100,000 | |
Shares, Issued (in shares) | 50,000 | |
Biolargo [Member] | Conversion Debt to Equity [Member] | ||
Number of Accredited Investors | 1 | |
Conversion of Stock, Amount Converted | $ | $ 50,000 |
Note 11 - Business Segment In_3
Note 11 - Business Segment Information (Details Textual) | 3 Months Ended |
Mar. 31, 2024 | |
Number of Operating Segments | 6 |
Note 11 - Business Segment In_4
Note 11 - Business Segment Information - Segment Information (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 4,760,000 | $ 3,742,000 | |
Stock option expense | (488,000) | (256,000) | |
Depreciation | (36,000) | (22,000) | |
Research and Development Expense | (784,000) | (565,000) | |
BioLargo corporate | (763,000) | (477,000) | |
Interest income (expense) | (12,000) | (48,000) | |
Tangible assets | 8,735,000 | $ 7,094,000 | |
Right of use, operating lease, net of amortization | 1,068,000 | 1,092,000 | |
Investment in South Korean joint venture | 18,000 | 19,000 | |
Total | 9,821,000 | 8,205,000 | |
Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | 18,000 | 19,000 | |
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | |||
Stock option expense | (429,000) | (195,000) | |
Depreciation | (10,000) | (6,000) | |
Research and Development Expense | (314,000) | (189,000) | |
BioLargo corporate | (1,244,000) | (799,000) | |
Interest income (expense) | (3,000) | (36,000) | |
Tangible assets | 1,079,000 | 942,000 | |
Right of use, operating lease, net of amortization | 380,000 | 394,000 | |
Total | 1,477,000 | 1,355,000 | |
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | 18,000 | 19,000 | |
Operating Segments [Member] | Odor-No-More [Member] | |||
Revenue from Contract with Customer, Including Assessed Tax | 4,575,000 | 3,543,000 | |
Depreciation | (5,000) | (4,000) | |
Research and Development Expense | 0 | 0 | |
BioLargo corporate | 1,798,000 | 1,387,000 | |
Interest income (expense) | (2,000) | (2,000) | |
Tangible assets | 5,870,000 | 4,624,000 | |
Right of use, operating lease, net of amortization | 0 | 0 | |
Total | 5,870,000 | 4,624,000 | |
Operating Segments [Member] | Odor-No-More [Member] | Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | 0 | 0 | |
Operating Segments [Member] | BLEST [Member] | |||
Tangible assets | 734,000 | 1,083,000 | |
Right of use, operating lease, net of amortization | 688,000 | 698,000 | |
Total | 1,422,000 | 1,781,000 | |
Operating Segments [Member] | BLEST [Member] | Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | 0 | 0 | |
Operating Segments [Member] | Clyra Medical [Member] | |||
Tangible assets | 949,000 | 432,000 | |
Right of use, operating lease, net of amortization | 0 | 0 | |
Total | 949,000 | 432,000 | |
Operating Segments [Member] | Clyra Medical [Member] | Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | 0 | 0 | |
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] | |||
Research and Development Expense | (80,000) | (32,000) | |
BioLargo corporate | (155,000) | (87,000) | |
Tangible assets | 65,000 | 4,000 | |
Right of use, operating lease, net of amortization | 0 | 0 | |
Total | 65,000 | 4,000 | |
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] | Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | 0 | 0 | |
Operating Segments [Member] | BEST [Member] | |||
BioLargo corporate | (66,000) | 0 | |
Tangible assets | 0 | 0 | |
Right of use, operating lease, net of amortization | 0 | 0 | |
Total | 0 | 0 | |
Operating Segments [Member] | BEST [Member] | Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | 0 | 0 | |
Operating Segments [Member] | BioLargo Canada [Member] | |||
Research and Development Expense | (80,000) | (135,000) | |
BioLargo corporate | (105,000) | (184,000) | |
Tangible assets | 38,000 | 50,000 | |
Right of use, operating lease, net of amortization | 0 | 0 | |
Total | 38,000 | 50,000 | |
Operating Segments [Member] | BioLargo Canada [Member] | Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | 0 | 0 | |
Operating Segments [Member] | BioLargo Engineering, Science & Technologies, LLC [Member] | |||
Revenue from Contract with Customer, Including Assessed Tax | 356,000 | 363,000 | |
Depreciation | (19,000) | (2,000) | |
Research and Development Expense | (352,000) | (245,000) | |
BioLargo corporate | (445,000) | (368,000) | |
Operating Segments [Member] | Clyra Segment [Member] | |||
Revenue from Contract with Customer, Including Assessed Tax | 0 | 6,000 | |
Stock option expense | (59,000) | (61,000) | |
Depreciation | (2,000) | (10,000) | |
Research and Development Expense | (121,000) | (134,000) | |
BioLargo corporate | (546,000) | (426,000) | |
Interest income (expense) | (7,000) | (10,000) | |
Consolidation, Eliminations [Member] | |||
Revenue from Contract with Customer, Including Assessed Tax | (171,000) | (170,000) | |
Research and Development Expense | 163,000 | $ 170,000 | |
Tangible assets | 0 | (41,000) | |
Right of use, operating lease, net of amortization | 0 | 0 | |
Total | 0 | (41,000) | |
Consolidation, Eliminations [Member] | Investment in South Korean Joint Venture [Member] | |||
Investment in South Korean joint venture | $ 0 | $ 0 |
Note 12 - Leases (Details Textu
Note 12 - Leases (Details Textual) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Operating Lease, Expense | $ 88,000 | $ 83,000 | |
Lessee, Operating Lease, Renewal Term (Year) | 4 years | ||
Increase (Decrease) in Operating Lease, Right-of-use Assets | $ 394,000 | ||
Lessee, Operating Lease, Discount Rate | 18% | ||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 7 years | 7 years | |
Lessee, Operating Lease, Liability, to be Paid | $ 2,042,000 |
Note 12 - Leases - Schedule of
Note 12 - Leases - Schedule of Future Minimum Lease Payments (Details) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
December 31, 2024 | $ 276,000 | |
December 31, 2025 | 282,000 | |
December 31, 2026 | 289,000 | |
December 31, 2027 | 296,000 | |
December 31, 2028 | 245,000 | |
Thereafter | 654,000 | |
Total minimum lease payments | 2,042,000 | |
Less imputed interest | (933,000) | |
Total operating lease liability | $ 1,090,000 | 1,109,000 |
BioLargo/ONM Lease [Member] | ||
December 31, 2024 | 122,000 | |
December 31, 2025 | 125,000 | |
December 31, 2026 | 129,000 | |
December 31, 2027 | 133,000 | |
December 31, 2028 | 79,000 | |
Total minimum lease payments | 588,000 | |
BLEST Lease [Member] | ||
December 31, 2024 | 154,000 | |
December 31, 2025 | 157,000 | |
December 31, 2026 | 160,000 | |
December 31, 2027 | 163,000 | |
December 31, 2028 | 166,000 | |
Thereafter | 654,000 | |
Total minimum lease payments | $ 1,454,000 |
Note 13 - Subsequent Events (De
Note 13 - Subsequent Events (Details Textual) | 1 Months Ended | |||
Apr. 01, 2024 shares | May 13, 2024 USD ($) shares | Mar. 31, 2024 shares | Dec. 31, 2023 shares | |
Common Stock, Shares, Issued (in shares) | 295,801,370 | 292,945,747 | ||
Subsequent Event [Member] | 2024 Warrants [Member] | ||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 10,000 | |||
Subsequent Event [Member] | Share-Based Payment Arrangement, Option [Member] | ||||
Stock Issued During Period, Shares, New Issues (in shares) | 194,818 | |||
Subsequent Event [Member] | Issuance to Two Accredited Investors [Member] | ||||
Common Stock, Shares, Issued (in shares) | 454,547 | |||
Proceeds from Issuance or Sale of Equity | $ | $ 150,000 | |||
Number of Accredited Investors | 2 | |||
Subsequent Event [Member] | BETI Common Stock [Member] | Conversion of BETI Common Stock to BioLargo Common Stock [Member] | ||||
Conversion of Stock, Shares Converted (in shares) | 20,000 | |||
Conversion of Stock, Shares Issued (in shares) | 378,788 |